Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:activeDuring |
gptkb:valdecoxib
|
| gptkbp:approves |
gptkb:European_Union
gptkb:United_States |
| gptkbp:barrelLength |
high for COX-2
low_for_COX-1 |
| gptkbp:brand |
gptkb:Bextra
|
| gptkbp:chemicalFormula |
sulfonamide
C16H14N2O2S |
| gptkbp:clinicalTrials |
Phase III
menstrual pain post-operative pain management management of chronic pain short-term management of pain |
| gptkbp:composedOf |
chemical synthesis
|
| gptkbp:contraindication |
hypertension
liver toxicity severe heart failure edema thrombotic events active peptic ulcer disease history of allergic reactions to sulfonamides |
| gptkbp:deployedTo |
safety concerns
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:endOfLife |
8 to 11 hours
|
| gptkbp:exportMarkets |
2005
|
| https://www.w3.org/2000/01/rdf-schema#label |
valdecoxib
|
| gptkbp:isATypeOf |
168869-08-0
|
| gptkbp:marketedAs |
gptkb:Bextra
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:patentStatus |
expired
|
| gptkbp:relatedTo |
NSAIDs
celecoxib rofecoxib |
| gptkbp:research_areas |
anti-inflammatory
analgesic |
| gptkbp:researchFocus |
pain management
anti-inflammatory effects safety profile cardiovascular safety |
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
cardiovascular events
skin reactions renal impairment gastrointestinal issues |
| gptkbp:triggerType |
COX-2 inhibitor
|
| gptkbp:usedFor |
pain relief
treatment of acute pain treatment of osteoarthritis treatment of rheumatoid arthritis |
| gptkbp:waterManagement |
urine
|
| gptkbp:year |
2001
|